Saliva swab may predict weight loss drug success
NCT ID NCT06814938
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether a biomarker found in saliva can predict how much weight people with obesity will lose when taking semaglutide. Researchers will compare weight changes in biomarker-positive and biomarker-negative participants over 24 weeks. The goal is to personalize obesity treatment, making it more effective and efficient.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Semaglutide
- What this could lead to
- If successful, this could lead to a simple saliva test that tells doctors which patients will benefit most from semaglutide for weight loss.
- What could go wrong
- This is a small, early-stage study focused on prediction, not a new treatment. The biomarker may not reliably predict response in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?